Category - Developments

Developments

Numinus to acquire Novamind creating leader in psychedelic therapy, research

Numinus (TSX:NUMI; OTCQX:NUMIF) agreed to acquire Novamind (CSE:NM; OTCQB:NVMDF;FSE:HN2) in a stock swap, by way of a court-approved plan of arrangement, for total consideration of about $26.2-million (Canadian). The...

April 13, 2022

Developments

Altamira Therapeutics provides business update

Altamira Therapeutics (NASDAQ:CYTO) provided a business update as it repositions around RNA therapeutics and continues to progress towards upcoming key catalysts with its non-RNA legacy programs. “We are...

April 12, 2022

Developments

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

The International Journal of Molecular Sciences (IJMS) published a peer-reviewed paper confirming Altamira Therapeutics’ (NASDAQ:CYTO) positive research findings regarding the in vitro efficacy and safety of its drug...

April 11, 2022

Developments

Viz.ai raises $100-million in Series D round

Closely-held Viz.ai raised $100-million to expand its artificial-intelligence platform designed to detect and triage strokes, heart attacks and aneurysms by scanning patient imagery. The Series D funding round led by...

April 6, 2022

Developments

Cannabotech partners with go NXT LVL to make oncology products in California

Closely-held Cannabotech of Israel entered a new strategic partnership with go NXT LVL of California to develop and manufacturing Cannabotech’s oncology products at go NXT LVL’s facilities in accordance with the...

April 6, 2022

Developments

Australian committee approves Claritas Phase 1 trial of R-107

The Australian Human Research Ethics Committee has approved Claritas Pharmaceuticals’ (TSXV:CLAS; OTC:CLAZF) submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney...

April 5, 2022

Developments

Clinigence, Nutex Health complete merger; listing on NASDAQ

Clinigence Holdings (OTC:CLNH) and Nutex Health Holdco completed their business combination. The newly combined company, which will continue under the new name, Nutex Health, brings together two complementary...

April 1, 2022

Developments

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio (NASDAQ:PALI) received a “study may proceed” letter from the FDA for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing...

March 22, 2022

Developments

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Closely-held Cytovale announced that a new study of its investigational IntelliSep test has been published in the peer-reviewed journal, PLOS ONE. The study demonstrated that the IntelliSep test has the potential to...

March 17, 2022

Developments

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Immunomic Therapeutics plans to start a Phase 1 clinical study of a plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer, using PharmaJet’s...

March 15, 2022

Category - Developments

Numinus to acquire Novamind creating leader in psychedelic therapy, research

Altamira Therapeutics provides business update

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

Viz.ai raises $100-million in Series D round

Cannabotech partners with go NXT LVL to make oncology products in California

Australian committee approves Claritas Phase 1 trial of R-107

Clinigence, Nutex Health complete merger; listing on NASDAQ

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

General

More